Abstract 199P
Background
To evaluate the efficacy and safety of Endostar combined with concurrent chemoradiothery(CCRT) in patients with locally advanced esophageal squamous cell carcinoma(ESCC).
Methods
From May 2017 to February 2021, 90 patients with unresectable thoracic ESCC, clinical staged as IB to IVB disease based on the 8th edition of the American Joint Committee on Cancer (stage IVB:only metastasis to supraclavicular/celiac lymph nodes) and local recurrence, were enrolled and randomly allocated in Endostar plus concurrent chemoradiothery (CCRT)(intervention group; n=44) and concurrent chemoradiothery (CCRT)(control group; n=46). Five or six cycles of Endostar (7.5mg/m2/24h ×120h, 7 days/cycle) were delivered in intervention group. The primary endpoint was overall survival(OS). The secondary end-points were progression-free survival (PFS), 1-year and 2-year overall survival rate and adverse events (AE).
Results
The median age was 63(interquartile range, 50-77) years in intervention group and 65(interquartile range, 52-79) years in control group. A total of 67 patients (74%) had stage III and IV disease. The Endostar-combined group had a significant higher complete response rate(ORR) than the control group((80% vs. 63.8%; P=0.084). Survival patients had a median follow-up of 51.5 months(interquartile range: 48.2-54.8 months). The median overall survival were 16.7m in Endostar-combined group and 12.8m in control group, respectively(p=0.054). The Endostar-combined group had a significantly higher 5-year overall survival rate(13.6% vs 0%; p=0.014). The were no significant differences in the incidence of grade 3 or higher toxic effects between the intervention group and control group(P>0.05).
Conclusions
This trial shows the combination of Endostar with concurrent chemoradiotheray (CCRT) was tolerable and provided higher ORR and 5-year overall survival rate over concurrent chemoradiothery (CCRT), and is very likely to provide promising survival benefit in patients with locally advanced ESCC.
Clinical trial identification
ChiCTR-IPR-16009926.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract